The Prochownik laboratory is interested in identifying and characterizing novel small molecule inhibitors of the Myc oncogenic transcription factor, which is commonly deregulated in many pediatric and adult cancers. Our approach has involved a variety of biological, biochemical, and biophysical techniques to study molecules that bind to the dimerization domain of Myc, alter its structure, and disrupt its interaction with Max — another transcription factor that is necessary for Myc-mediated transformation. We have identified a number of such molecules and mapped their binding sites on Myc. Current research efforts are aimed at characterizing new molecules and optimizing the properties of previously identified ones.
- Home
- About Us
- Divisions
- Adolescent and Young Adult Medicine
- Allergy and Immunology
- Blood and Marrow Transplantation and Cellular Therapies
- Cardiology
- Child Advocacy
- Emergency Medicine
- Endocrinology
- Gastroenterology, Hepatology and Nutrition
- General Academic Pediatrics
- Genetic and Genomic Medicine
- Health Informatics
- Hematology-Oncology
- Infectious Diseases
- Nephrology
- Neurology and Child Development
- Newborn Medicine
- Paul C. Gaffney Division of Pediatric Hospital Medicine
- Pulmonology
- Rheumatology
- Centers & Institutes
- Center for Pediatric Research in Obesity and Metabolism
- Center for Rare Disease Therapy
- Children's Neuroscience Institute
- Cystic Fibrosis Research Center
- Institute for Infection, Inflammation, and Immunity in Children
- Pediatric Asthma Center
- Pediatric Institute for Heart Regeneration and Therapeutics
- Richard King Mellon Foundation Institute for Pediatric Research
- Pittsburgh Vaccine Trials Unit
- The Pittsburgh Study
- Research
- Diversity
- Education
- Faculty Affairs
- News
- People
- Podcasts